Hub Cyber Security Seeks Shareholder Approval for 1B Share Authorization, Reverse Splits, and Evofem Warrant Unlock

summarizeSummary

Hub Cyber Security's annual meeting proxy seeks approval for a 1B share authorization, reverse splits up to 1-for-1,000, and the removal of a 4.99% blocker on Evofem-related pre-funded warrants — moves that could massively dilute existing holders but are aimed at maintaining Nasdaq listing and funding operations.

check_boxKey Events · Corporate Governance and Compliance · HUBC

• 1B Share Authorization Sought

  To accommodate the Evofem private placement and future equity raises, the board proposes increasing authorized ordinary shares from 66.7M to 1.0B — a 15x jump that enables massive potential dilution.

• Reverse Split Authorization Up to 1-for-1,000

  Shareholders are asked to approve one or more reverse splits in an aggregate ratio range of 1-for-5 to 1-for-1,000, with the Board retaining discretion on the exact ratio and timing, primarily to regain Nasdaq minimum bid compliance.

• Evofem Warrant Blocker Removal

  Proposal 6 seeks to lift the 4.99% beneficial ownership limitation on pre-funded warrants issued in the Evofem transaction, allowing exercise of up to ~40M additional shares and triggering severe dilution for existing holders.

• Director Designation and Committee Pay

  Vineet Malhotra is nominated as a Class I director until 2029. Additionally, members of the Transactions and Restructuring Committee would receive up to $200K (chair) and $125K (members) through Dec 2026, payable only after a $30M equity financing.

auto_awesomeAnalysis · HUBC · Technology

The proxy statement for Hub Cyber Security's September 8 annual meeting contains several high-stakes proposals. To maintain Nasdaq listing and fund operations, the board is asking shareholders to greenlight a massive authorized share increase to 1 billion shares — a 15x jump from the current 66.7 million — and to authorize reverse splits up to 1-for-1,000. These are survival tools: the reverse split aims to keep the stock above the $1 minimum bid, while the share increase provides headroom for the Evofem-related private placement and future dilutive financings. The proxy also seeks approval to lift the 4.99% blocker on pre-funded warrants issued in the Evofem deal, which would unlock up to ~40 million additional shares and dramatically dilute existing holders. Against a backdrop of a going-concern warning, massive losses, and a stock trading near its all-time low, these proposals signal a company fighting for its listing and scrambling for capital flexibility — but at severe cost to current shareholders.